JPMorgan Downgrades Mereo BipPharma Group (MREO) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MREO Hot Sheet
Price: $0.30 +3.45%
Rating Summary:
3 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
3 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
JPMorgan analyst Priyanka Grover downgraded Mereo BipPharma Group (NASDAQ: MREO) from Neutral to Underweight.
For an analyst ratings summary and ratings history on Mereo BipPharma Group click here. For more ratings news on Mereo BipPharma Group click here.
Shares of Mereo BipPharma Group closed at $0.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Double Downgrades Aardvark Therapeutics Inc (AARD) to Market Perform
- Cenovus Energy (CVE) Tops Q3 EPS by 79c
- Magnite (MGNI) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
DowngradesRelated Entities
JPMorgan, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
